- Name
- Ipamorelin
- API
- Ipamorelin
- Dosage5mg
- Packing3 ml vial
Ipamorelin is a synthetic peptide with potent growth hormone–releasing (GHR) activity that has attracted significant interest in the bodybuilding community for its potential effects on muscle gain and fat loss. Its mechanism is broadly similar to that of GHRP‑6 (growth hormone–releasing hexapeptide), in that it acts as a growth hormone secretagogue rather than supplying growth hormone directly. These growth hormone–stimulating effects are what appeal to many athletes and bodybuilders, as they may influence how much muscle is built and how efficiently fat is metabolized. In practice, some users report taking ipamorelin at doses around 200–300 mcg, two to three times per day, administered with a small insulin syringe. Individuals typically begin at the lower end of the range because side effects such as headache or a brief “head‑rush” sensation can occur. Although ipamorelin can theoretically be used at different times of day, many aim to administer it about 30–45 minutes before training to coincide with the induced pulse of growth hormone and potentially support training‑related adaptations. Experimental work examining ipamorelin’s influence on bone growth, body weight, and growth hormone release has yielded notable findings. In one study, subjects received varying doses over a 15‑day period to assess physiological responses. The treatment produced a clear, dose‑dependent increase in body‑weight gain, yet did not significantly alter total IGF‑I levels or typical blood markers of bone formation. Importantly, the number of cells in the widened region of the tibia (shinbone) remained essentially unchanged, indicating no marked stimulation of bone or cartilage overgrowth. This pattern suggests that ipamorelin may promote muscle gain without the same degree of risk for skeletal deformities sometimes associated with excessive growth hormone or IGF‑I exposure.